سعر دوكسوروبيسين إيبوي 10 مجم فيال 2025

Doxorubicin Ebewe 10 mg doxorubicin (10 mg (2 mg/ml)), Sandoz / B.P. Pharma, Egypt.

• As a component of multi-agent adjuvant chemotherapy for breast cancer and for other labeled malignancies (e.g. acute leukemias, lymphomas, sarcomas, carcinomas) per specialist protocols.Population: Adults / oncology per protocolDailyMed / FDA

• Alopecia, nausea/vomiting, mucositis, myelosuppression, red-orange urine discoloration, cardiotoxicity, local tissue necrosis if extravasated.International label, equivalent formulation · DailyMed / FDA

• Severe persistent myelosuppression; severe hepatic impairment; recent myocardial infarction / severe myocardial insufficiency; severe arrhythmias; previous lifetime cumulative anthracycline doses approaching cardiotoxic thresholds; hypersensitivity to doxorubicin or anthracyclines.International label, equivalent formulation · DailyMed / FDA

• BOXED WARNING: cardiomyopathy / congestive heart failure risk increases with cumulative dose; secondary malignancies; extravasation injury; severe myelosuppression.International label, equivalent formulation · DailyMed / FDA
• Administer only under supervision of a physician experienced in cancer chemotherapy; monitor CBC, cardiac function (LVEF), and hepatic function.International label, equivalent formulation · DailyMed / FDA

• Paclitaxel / trastuzumab / other cardiotoxic agentsMajorPaclitaxel / trastuzumab / other cardiotoxic agents: may increase cardiotoxicity risk.DailyMed / FDA
• CYP3A4 / CYP2D6 / P-gp inhibitors or inducersModerateCYP3A4 / CYP2D6 / P-gp inhibitors or inducers: may alter doxorubicin exposure.DailyMed / FDA

• Can cause fetal harm. Advise females of reproductive potential of risk and use effective contraception. Avoid during pregnancy unless clearly needed.International label, equivalent formulation · DailyMed / FDA
• Present in human milk; discontinue breastfeeding during treatment and for a period after the last dose per US label.International label, equivalent formulation · DailyMed / FDA

• Doxorubicin: Intercalates DNA and inhibits topoisomerase II, disrupting DNA replication and transcription; generates free radicals contributing to cytotoxicity and cardiotoxicity.